HC Wainwright Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $570.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 24.00% from the company’s previous close.

Other analysts have also recently issued reports about the company. Truist Financial began coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a “buy” rating and a $385.00 price target on the stock. BMO Capital Markets upped their price target on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Needham & Company LLC upped their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Finally, Chardan Capital upped their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $457.16.

Read Our Latest Analysis on ALNY

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $459.66 on Friday. The stock has a market cap of $60.25 billion, a PE ratio of -186.10 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $484.21. The stock’s 50 day simple moving average is $451.37 and its 200-day simple moving average is $345.60.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the sale, the executive vice president owned 27,438 shares in the company, valued at approximately $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president owned 25,231 shares in the company, valued at $11,405,673.55. The trade was a 8.82% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $243,000. GAMMA Investing LLC lifted its stake in shares of Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 77 shares during the period. NorthCrest Asset Manangement LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at $323,000. Everhart Financial Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 12.0% during the first quarter. Everhart Financial Group Inc. now owns 1,787 shares of the biopharmaceutical company’s stock valued at $483,000 after acquiring an additional 191 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Alnylam Pharmaceuticals by 14.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 14,404 shares of the biopharmaceutical company’s stock valued at $3,889,000 after acquiring an additional 1,838 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.